Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment
- 15 September 2005
- journal article
- Published by Elsevier in Schizophrenia Research
- Vol. 77 (2-3) , 253-260
- https://doi.org/10.1016/j.schres.2005.04.001
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophreniaProceedings of the National Academy of Sciences, 2004
- Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene ( GRM3 ) with schizophreniaPsychiatric Genetics, 2003
- 5HT2A and 5HT2C Receptor Polymorphisms And Predicting Clinical Response to Olanzapine in SchizophreniaJournal of Clinical Psychopharmacology, 2002
- d-Cycloserine added to risperidone in patients with primary negative symptoms of schizophreniaSchizophrenia Research, 2002
- Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapineBiological Psychiatry, 2002
- Placebo-Controlled Trial of d-Cycloserine Added to Conventional Neuroleptics, Olanzapine, or Risperidone in SchizophreniaAmerican Journal of Psychiatry, 2002
- A Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics in Patients With SchizophreniaArchives of General Psychiatry, 1999
- PHARMACOLOGY AND FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTORSAnnual Review of Pharmacology and Toxicology, 1997
- Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1995
- Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugsJournal of Neuroscience, 1995